86 -11 (61) 2023 — Khakimova G.G., Jumaniyozov Kh.I. — МODERN THERAPY OF CERVICAL CANCER

МODERN THERAPY OF CERVICAL CANCER

Khakimova G.G., Tashkent Pediatric Medical Institute, Tashkent City Branch of the Republican Specialized Scientific Practical Medical Center of Oncology and Radiology, Nano Medical Clinic

Jumaniyozov Kh.I., Tashkent Pediatric Medical Institute,Tashkent City Branch of the Republican Specialized Scientific Practical Medical Center of Oncology and Radiology, Nano Medical Clinic

Khakimova Sh.G., Tashkent Pediatric Medical Institute,Tashkent City Branch of the Republican Specialized Scientific Practical Medical Center of Oncology and Radiology, Nano Medical Clinic

Talipov O.A., Tashkent Pediatric Medical Institute,Tashkent City Branch of the Republican Specialized Scientific Practical Medical Center of Oncology and Radiology, Nano Medical Clinic

Salohiddinov H.A., Tashkent Pediatric Medical Institute,Tashkent City Branch of the Republican Specialized Scientific Practical Medical Center of Oncology and Radiology, Nano Medical Clinic

Kadirov Sh.Sh., Tashkent Pediatric Medical Institute,Tashkent City Branch of the Republican Specialized Scientific Practical Medical Center of Oncology and Radiology, Nano Medical Clinic

Tashmetov M.N. Tashkent Pediatric Medical Institute,Tashkent City Branch of the Republican Specialized Scientific Practical Medical Center of Oncology and Radiology, Nano Medical Clinic

Resume
Cervical cancer is the fourth most common cancer in women worldwide and is responsible for over
300,000 deaths worldwide. The causative agent of cervical cancer is persistent infection with high-risk
human papillomavirus subtypes, and viral oncoproteins E5, E6, and E7 interact with human factors to
induce and maintain a malignant phenotype. This review describes the mechanisms behind the onset and
development of cervical cancer and discusses in detail promising and effective new treatment options for
cervical cancer, including immunotherapy, targeted therapy and combination therapy.
Key words: cervical cancer; HPV E6/E7 oncoproteins; target therapy; immune checkpoint inhibitors;
combination therapy.

First page

525

Last page

535

For citation: Khakimova G.G., Jumaniyozov Kh.I., Khakimova Sh.G., Talipov O.A., Salohiddinov H.A., Kadirov Sh.Sh., Tashmetov M.N. – МODERN THERAPY OF CERVICAL CANCER //New Day in Medicine 2023 11(61): 525-535 https://newdaymedicine.com/index.php/2023/12/24/l-664/

LIST OF REFERENCES:

  1. Каприн А.Д., Старинский В.В., Шахзадова А.О. Состояние онкологической помощи населению России в 2021г.
  2. Cancer statistics, 2022
  3. IARC monographs on the evaluation of carcinogenic risks to humans. IARC (Int. Agency Res. Cancer) Monogr. Eval. Carcinog. Risks Hum. 2010; 93doi: 10.1136/jcp.48.7.691-a.
  4. Johnson C.A., James D., Marzan A., Armaos M. Cervical cancer: an Overview of pathophysiology and management. Semin. Oncol. Nurs. 2019 doi: 10.1016/j.soncn.2019.02.003.
  5. Walboomers J.M.M., Jacobs M.v., Manos M.M., Bosch F.X., Kummer J.A., Shah K.v., Snijders P.J.F., Peto J., Meijer C.J.L.M., Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 1999; 189 doi: 10.1002/(SICI)1096- 9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F.
  6. zur Hausen H. Papillomaviruses in the causation of human cancers – a brief historical
    account. Virology. 2009
  7. Crosbie E.J., Einstein M.H., Franceschi S., Kitchener H.C. Human papillomavirus and cervical cancer. Lancet. 2013 doi: 10.1016/S0140-6736(13)60022-7.
  8. de Sanjosé S., Diaz M., Castellsagué X., Clifford G., Bruni L., Muñoz N., Bosch F.X. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect. Dis. 2007; 7 doi: 10.1016/S1473- 3099(07)70158-5.